招银国际:升三生制药(01530.HK)目标价至37.67港元 维持“买入”评级

智通财经
30 Jul
【招银国际:升三生制药(01530.HK)目标价至37.67港元 维持“买入”评级】智通财经APP获悉,招银国际发布研报称,三生制药(01530.HK)与辉瑞就707(PD-1/VEGF双抗)达成的全球(除中国)授权协议正式生效。维持“买入”评级,目标价由28.32港元上调至37.67港元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10